Cardiovascular Safety of Dipeptidyl Peptidase 4 Inhibitors Compared With Insulin or Sulfonylureas Added to Metformin Among Older People With Diabetes Living in Long-Term Care Facilities

To examine the cardiovascular safety of dipeptidyl peptidase 4 (DPP-4) inhibitors compared with long-acting insulin or sulfonylurea initiation added to metformin in older people with diabetes in long-term care facilities (LTCFs).